These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 1778314

  • 1. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
    Gupta RK, Saxena SN, Sharma SB, Ahuja S.
    Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
    [Abstract] [Full Text] [Related]

  • 2. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals.
    Sato Y, Sato H.
    Dev Biol Stand; 1991; 73():251-62. PubMed ID: 1778317
    [Abstract] [Full Text] [Related]

  • 3. Effect of heptakis (2,6-0-dimethyl)beta-cyclodextrin on cell growth and the production of pertussis toxin and filamentous hemagglutinin in Bordetella pertussis.
    Suzuki Y, Imaizumi A, Ginnaga A, Sato H, Sato Y.
    Dev Biol Stand; 1985; 61():89-92. PubMed ID: 2872134
    [Abstract] [Full Text] [Related]

  • 4. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
    Sato Y, Sato H.
    Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
    Morokuma K, Ginnaga A, Nishihara T, Tsunoda S, Furukawa M, Aihara K, Sakoh M.
    Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
    [Abstract] [Full Text] [Related]

  • 8. Production and purification of Bordetella pertussis toxin.
    Ju CL, Sheu GC, Cheng Y, Lu CH.
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1997 May; 30(2):72-83. PubMed ID: 10592813
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P, Rodmalm K, Wrangsell G, Larsson U, Svenson SB, Cowell JL, Undén A, Bartfai T.
    Dev Biol Stand; 1991 May; 73():111-20. PubMed ID: 1778305
    [Abstract] [Full Text] [Related]

  • 12. Optimization of immunization schedule to standardize antibody response in mice to pertussis vaccines.
    Tiru M, Jäätmaa E, Gillenius P, Askelöf P.
    Dev Biol Stand; 1985 May; 61():469-75. PubMed ID: 2872128
    [Abstract] [Full Text] [Related]

  • 13. Comparative biological activities of acellular pertussis vaccines produced by Kitasato.
    Watanabe M, Izumiya K, Sato T, Yoshino K, Nakagawa N, Ohoishi M, Hoshino M.
    Kitasato Arch Exp Med; 1991 Apr; 64(1):31-42. PubMed ID: 1798236
    [Abstract] [Full Text] [Related]

  • 14. Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine.
    van Straaten-van de Kappelle I, van der Gun JW, Marsman FR, Hendriksen CF, van de Donk HJ.
    Biologicals; 1997 Mar; 25(1):41-57. PubMed ID: 9167008
    [Abstract] [Full Text] [Related]

  • 15. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
    Winsnes R, Lønnes T, Møgster B, Berdal BP.
    Dev Biol Stand; 1985 Mar; 61():353-65. PubMed ID: 2872124
    [Abstract] [Full Text] [Related]

  • 16. Further evaluation of the pertussis component vaccine produced by apoceruloplasmin affinity chromatography.
    Ginnaga A, Morokuma K, Furukawa S, Shigaki T, Katsuki N, Aihara K, Oka T, Sakoh M, Tamura C, Imaizumi A.
    Dev Biol Stand; 1991 Mar; 73():233-41. PubMed ID: 1778315
    [Abstract] [Full Text] [Related]

  • 17. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A, Pizza M, Gross R, Perugini M, Arico B, Domenighini M, Rappuoli R.
    Tokai J Exp Clin Med; 1988 Mar; 13 Suppl():217-22. PubMed ID: 2483870
    [Abstract] [Full Text] [Related]

  • 18. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS, Lake AM, Wilson ME, Willingham FF, Shematek J, Moulton L, Deforest A, Halsey NA.
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [Abstract] [Full Text] [Related]

  • 19. Development of acellular pertussis vaccines.
    Sato Y, Sato H.
    Biologicals; 1999 Jun; 27(2):61-9. PubMed ID: 10600185
    [Abstract] [Full Text] [Related]

  • 20. [Properties of an acellular preparation of Bordetella pertussis and its analysis after centrifugation in saccharose gradient].
    Letowska I, Kaczurba E, Schiller B.
    Med Dosw Mikrobiol; 1993 Jun; 45(3):289-94. PubMed ID: 8189799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.